-

01:16:56 AM

Latest CYDY Stock Market News

CYDY - Cytodyn Inc

09/17/21 8:00 AM

OTC : CYDY

covid-19

Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit

A group of long-time stockholders of CytoDyn Inc. that has nominated five highly experienced director candidates to serve on the Company’ s Board of Directors today announced that Bruce Patterson, M.D., one of the candidates, attended and presented at the International COVID Summit, held in Rome, Italy from September 12-14, 2021. Dr. Patterson was one of three...

RHEA-AI

positive

09/15/21 10:18 AM

OTC : CYDY

Glancy Prongay & Murray LLP Announces Investigation of CytoDyn Inc.

Glancy Prongay& Murray LLP announces its investigation of CytoDyn Inc. concerning the Company and its directors’ and officers’ possible violations of state laws. If you purchased CytoDyn Inc. stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please...

RHEA-AI

neutral

09/13/21 6:00 AM

OTC : CYDY

conferences

CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D.,

RHEA-AI

neutral

09/09/21 8:29 PM

OTC : CYDY

clinical trialcovid-19

CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5

RHEA-AI

neutral

09/07/21 8:30 AM

OTC : CYDY

Group of CytoDyn Stockolders Responds to Misleading Company News Release

A group of long-time stockholders of CytoDyn Inc. that has nominated five highly experienced director candidates to serve on the Company’ s Board of Directors today responded to a news release issued by CYDY on September 3, 2021 that completely misrepresented a voluntary stipulation filed by the Nominating Stockholders in the litigation initiated by the...

RHEA-AI

negative

09/02/21 6:40 PM

OTC : CYDY

covid-19

CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials

CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D.,

RHEA-AI

neutral

09/02/21 5:32 PM

OTC : CYDY

CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws

The Board of Directors of CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today issued a statement to shareholders commenting on the Court Order entered yesterday by a United States District Court Judge in the lawsuit brought by CytoDyn against the...

RHEA-AI

negative

09/02/21 8:30 AM

OTC : CYDY

Group of CytoDyn Stockholders Warns Stockholders of Board’s Continued Value Destruction and Failures

A group of long-time stockholders of CytoDyn Inc. that has nominated five highly experienced director candidates to serve on the Company’ s Board of Directors today released a letter to fellow stockholders outlining recent ill-advised actions and announcements made by CYDY’ s current leadership that have further destroyed the Company’ s value and damaged...

RHEA-AI

neutral

08/26/21 5:02 PM

OTC : CYDY

management

CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs

Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led the CMC strategy and successfully submitted a monoclonal antibody based BLA (Dupixent approved in

RHEA-AI

very positive

08/26/21 8:30 AM

OTC : CYDY

Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director Nominees

A group of long-time stockholders of CytoDyn Inc. that has nominated five highly experienced director candidates to serve on the Company’ s Board of Directors today announced that it has filed a lawsuit in the Delaware Court of Chancery seeking to force CYDY to allow stockholders to vote for the Group’ s nominees. CYDY previously commenced a meritless lawsuit...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next